Reviewer's report

Title: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (Flr-B/FOx) according to extension of metastatic disease

Version: 3 Date: 14 September 2012

Reviewer: Paolo Correale

Reviewer's report:

The study by Ruera et al describes the results of a retrospective study aimed to evaluate the prognostic value of KRAS in colo-rectal cancer patients undergone bevacizumab + triplet chemotherapy.

In the present form the manuscript appears well written and very clear in term of design and objectives and obtained results.

Introduction, results and discussion are well balanced.

My only consideration at present, regards the non-significant statistical differences in OS, PFS and OS in patients O/MM. I believe that it could be dependent by the relatively low number of cases. I think that this point deserves a small comment in the text.

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I have no competing interests